Isha Jain

Lots of safety/efficacy work still to be done, but hypoxia-based therapies could have broad applications from rare mitochondrial diseases to age-associated neurodegeneration. We are interested in additional partnerships in academia/industry to continue this work. Send me a DM!

Huge congratulations to all co-authors -- first-author Skyler Blume and all the folks at Maze (Maarten Hoek, Chris Sinz, Gijs Grotenbreg, Eric Green, Vyas Ramanan and more)!

Key Findings:
✅ HypoxyStat induces hypoxia comparable to 11% O₂ inhalation (~4500m altitude).
✅ Extends lifespan 3-4x in the Ndufs4KO mouse model of mitochondrial disease.
✅ Reverses disease pathology—even at late stages!

💊 Enter HypoxyStat—a small molecule that increases how tightly hemoglobin holds onto oxygen, thereby reducing oxygen release into tissues and causing hypoxia without requiring specialized gas environments or moving to the mountains!

A quick thread: mitochondrial dysfunction causes an imbalance in oxygen supply and demand, leading to tissue hyperoxia. We've previously shown that inhaled hypoxia can dramatically extend lifespan in disease models. But how do we translate this into a practical therapy?

PS. We're hiring! If you're excited about oxygen or redox cofactor (vitamin) metabolism come work with us @ArcInstitute @GladstoneInst @UCSF! Postdoc candidates, Apply here: grnh.se/7c94a5004us

🚨 New paper alert! 🚨
Check out our latest work on HypoxyStat, a small-molecule therapy that increases oxygen-hemoglobin affinity and provides a practical form of hypoxia therapy. A great collaboration with Maze Therapeutics
🔗 Paper: doi.org/10.1016/j.ce... @cp-cell.bsky.social

Slowly making my way over here. Excited to connect with you all! We study all things oxygen, redox and vitamins!